Barclays PLC Anebulo Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 399 shares of ANEB stock, worth $941. This represents 0.0% of its overall portfolio holdings.
Number of Shares
399Holding current value
$941% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ANEB
# of Institutions
22Shares Held
22.2MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA15.5MShares$36.5 Million25.71% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.04MShares$7.17 Million0.29% of portfolio
-
Mangrove Partners New York, NY2.53MShares$5.96 Million0.77% of portfolio
-
Morgan Stanley New York, NY399KShares$942,5930.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA307KShares$723,4340.0% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $60.5M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...